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ABSTRACT The clinical course of intensive care unit (ICU) patients may be complicated by a large
spectrum of lower respiratory tract infections (LRTI), defined by specific epidemiological, clinical and
microbiological aspects.
A European network for ICU-related respiratory infections (ENIRRIs), supported by the European
Respiratory Society, has been recently established, with the aim at studying all respiratory tract infective
episodes except community-acquired ones. A multicentre, observational study is in progress, enrolling
more than 1000 patients fulfilling the clinical, biochemical and radiological findings consistent with a
LRTI. This article describes the methodology of this study. A specific interest is the clinical impact of non-
ICU-acquired nosocomial pneumonia requiring ICU admission, non-ventilator-associated LRTIs occurring
in the ICU, and ventilator-associated tracheobronchitis. The clinical meaning of microbiologically negative
infectious episodes and specific details on antibiotic administration modalities, dosages and duration are
also highlighted. Recently released guidelines address many unresolved questions which might be answered
by such large-scale observational investigations. In light of the paucity of data regarding such topics, new
interesting information is expected to be obtained from our network research activities, contributing to
optimisation of care for critically ill patients in the ICU.
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Introduction
The clinical spectrum of lower respiratory tract infections (LRTI) potentially affecting patients managed in
the intensive care unit (ICU) includes different diseases with peculiar epidemiological, clinical and
microbiological aspects. Different scenarios might be identified by physicians dealing with nosocomial
respiratory infections. On one hand, some hospitalised patients may develop nosocomial pneumonia
outside the ICU, but then be transferred to the ICU because of the development of organ failure and the
need for critical care support: these patients are considered to have non-ICU-acquired nosocomial
pneumonia requiring ICU admission [1–3]. On the other hand, the clinical course of patients already
admitted to the ICU, for a variety of reasons, may be complicated by the occurrence of a LRTI: these
patients are considered to have an ICU-acquired pneumonia (ICUAP). ICUAP may affect patients who are
undergoing mechanical ventilation or during spontaneous breathing [4, 5]. Hence, this definition includes
both ventilator-associated pneumonia (VAP) and non-ventilator ICU-acquired pneumonia (NV-ICUAP).
Furthermore, nosocomial pneumonia may also occur in patients who are noninvasively ventilated in the
ICU or in those with a tracheostomy but already weaned from the ventilator: these represent a specific
subgroup of patients with NV-ICUAP. Finally, when ICU ventilated patients match the clinical,
biochemical and microbiological criteria for VAP without the presence of a new infiltrate on the chest
radiographs, a diagnosis of ventilator-associated tracheobronchitis (VAT) may be formulated [6]. All these
entities are leading infections in critically ill patients and account for prolonged mechanical ventilation
and length of stay, and poor outcome. It has been documented that both VAP and hospital-acquired
pneumonia (HAP) are prevalent severe hospital-acquired infections, accounting for more than 20% of all
hospital-acquired infections, with an attributable mortality rate ranging between 20% and 50% and an
estimated extra-cost of approximately USD 40000 per patient [7]. However, their relative clinical impact
and epidemiological profile is not yet well understood [8–10].
The European Respiratory Society (ERS) is heavily involved in the coordination of investigational activities
in respiratory medicine across Europe through its funding of clinical research collaborations (CRCs)
aiming to advance scientific and clinical research within a specific disease area (https://www.ersnet.org/
research/clinical-research-collaborations). The increasingly relevance ERS is giving to the development of
CRCs as a crucial tool to promote networking and research is recognised by the institution of a CRC
director as part of the Science Council. Among the CRCs developed within the respiratory infections
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assembly of the ERS, a European network for ICU-related respiratory infections (ENIRRIs) has been
recently established with the objective of investigating the epidemiological, clinical and microbiological
profile of all the respiratory infectious episodes, aside from community-acquired ones, occurring in
critically ill patients managed in the ICU. This article describes the methodology of the first project
developed as part of ENIRRIs project.
Study methodology
This is a European, multicentre, multinational, prospective, observational study enrolling consecutive
critically ill patients affected by nosocomial respiratory infections in the ICU. The following conditions are
considered for inclusion in this trial.
1) Out of ICU HAP: hospital length of stay ⩾48 h plus new or progressive radiological pulmonary infiltrate
together with at least two of the following: temperature >38°C or <36°C; leukocytosis >12000 mm−3 or
leukopenia <4000 mm−3; or purulent respiratory secretions.
2) NV-ICUAP: ICU length of stay ⩾48 h and out of mechanical ventilation ⩾48 h plus new or progressive
radiological pulmonary infiltrate together with at least two of the following: temperature >38°C or <36°C;
leukocytosis >12000 mm−3 or leukopenia <4000 mm−3; or purulent respiratory secretions.
3) VAP: tracheal intubation/tracheostomy and mechanical ventilation ⩾48 h plus new or progressive
radiological pulmonary infiltrate together with at least two of the following: temperature >38°C or <36°C;
leukocytosis >12000 mm−3 or leukopenia <4000 mm−3; or purulent respiratory secretions.
4) VAT: As for VAP without a new or progressive radiological pulmonary infiltrate.
The primary objective of the study is to compare mortality among these different pneumonia categories.
Secondary objectives are to compare epidemiological patterns with particular emphasis on individual risk
factors, microbiological profile, clinical characteristics and therapeutic interventions (i.e. severity of the
disease and duration of antimicrobial therapy), along with other common outcome measures (i.e. length of
ICU stay and length of organ support).
All consecutive adult patients admitted to the ICU of participating sites and presenting with nosocomial
pneumonia are eligible for the study. Enrolment is performed during a 12-month period, with a maximum
of 50 cases per centre. ICUs which take part in the ENIRRIs project agree to prospectively collect the data,
clearly document in the medical chart all the information required for the data analysis and transfer the
data to the principal investigators of the project. Specific inclusion criteria are: age ⩾18 years; diagnosis of a
nosocomial respiratory infection, as defined earlier; admission to either the ICU or a high-dependency unit
(the patient may be admitted to the ICU with nosocomial pneumonia or may develop pneumonia during
their ICU stay); and informed consent (if required according to local legislation). Case report forms are
FIGURE 1 European network for
ICU-related respiratory infections
(ENIRRIs) participating centres.
Number of centres: Italy n=6; Spain
n=5; France n=2; Portugal n=2;
Germany n=2; the Netherlands n=2;
Belgium n=1; Greece n=1; Ireland
n=1; Czech Republic n=1; Poland
n=1; Serbia n=1; Croatia n=1;
Argentina n=1 (not shown on map);
Brazil n=1 (not shown on map).
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provided to record the data, and will be electronic and web-based. All epidemiological (type of admission,
previous treatments and hospitalisations, previous or other on-going infections, and specific risk factors),
clinical (severity of the disease, type and number of organ failures, type and duration of antibiotics,
outcome measures) and microbiological information (including the adopted diagnostic approach) required
by the electronic case report forms are clearly documented and retrievable from the patient’s medical chart
(either paper or electronic). All data are anonymous and only the local principal investigator has access to
the decoding list in order to link the enrolment number with the corresponding patient. All infections are
microbiologically confirmed: sputum in non-ventilated patients, tracheobronchial aspirates (TBA) in
intubated/tracheotomised patients, and/or bronchoscopic or blind bronchoalveolar lavage (BAL), within the
first 24 h of clinical diagnosis. Diagnostic thresholds are: BAL ⩾104 colony-forming units per mL, and
sputum or TBAs ⩾105 colony-forming units per mL, or any threshold if the patient had antibiotic
treatment. The final goal of this observational study is to recruit at least 1000 patients across 15 countries,
in Europe and Latin America (figure 1). Study results will be disseminated in the form of annual reports,
conference abstracts and peer-reviewed publications. The ENIRRIs study group will follow the International
Committee of Medical Journal Editors recommendations regarding authorship.
The impact of ENIRRIs research
The epidemiological and clinical evaluation of LRTIs acquired in the hospital setting remains a topic of
outstanding relevance. A new definition, a ventilator-associated event (VAE), has been recently introduced
in the US scientific debate, grouping all the conditions that result in a significant and sustained
deterioration of oxygenation, independent of the infectious nature of the underlying process. However, this
definition has been largely observed to be neither sensitive nor specific for VAP, and to be inappropriate
for surveillance purposes: the 2016 American Thoracic Society (ATS)/American College of Chest
Physicians (ACCP) guidelines have been drafted using only HAP or VAP, and consider VAE, ventilator-
associated complications, infectious ventilator-associated complications, etc. only as a quality of care
indicators [11].
Very little is known about the actual impact of nosocomial pulmonary infections in non-ventilated
patients, which represent a large portion of the patients admitted to the ICU with respiratory failure. In
this setting, the type of respiratory sampling (invasive versus noninvasive) and of microbiological culture
(qualitative versus semi-quantitative versus quantitative) is still a matter of debate.
Furthermore, the latest 2016 ATS/ACCP guidelines recognise several grey areas where recommendations
are mostly based on expert opinions (microbiological diagnosis, use of biomarkers, duration of therapy,
clinical impact and definition of VAT, and use of inhaled antibiotics). We believe that results from the
ENIRRIs study will inform the scientific community and will be of a special help in addressing these
clinical and research questions. Importantly, in the absence of any artificial airway (tracheal tube or
tracheostomy), the microbiological characterisation of nosocomial pneumonia may be further complicated
by the suboptimal reliability of sputum specimens or by the limited feasibility of awake bronchoscopic
BAL in spontaneously breathing patients with pneumonia complicated by respiratory failure. However,
interventional trials that aim to verify the efficacy of new antimicrobial drugs are focused on both
populations (ventilator/non-ventilator-associated pneumonia), testing a complex case mix which includes
different types of patients, infections and bacteria [12].
From a microbiological point of view, it is well known that VAP occurring after 96 h of mechanical
ventilation (late-onset VAP) is typically caused by multidrug-resistant bacteria and requires a prompt
broad-spectrum antibiotic treatment [13]. However, recent data show that a large portion of ICU patients
with early-onset VAP are infected with nosocomial flora, since they share many risk factors with
long-term ICU admitted subjects. Similarly HAP, NV-ICUAP and VAT may be caused by
multidrug-resistant bacteria but, to date, no studies have specifically addressed this topic [14].
Nevertheless, all these pneumonia categories may be clinically confirmed without identifying any pathogen
and the clinical relevance and therapeutic approach of such microbiologically negative nosocomial
pneumonia is under discussion [15, 16]. Finally, antibiotic strategies, as empirical approach, suggested by
current guidelines do not take into account the abovementioned crucial considerations and, although
providing general useful indications, may lack validity in many specific settings [16].
In light of the paucity of data regarding this incredibly complex scenario, new insights are absolutely
warranted in order to increase our knowledge and improve the outcome of ICU patients with lower
respiratory tract nosocomial infections.
This protocol from the ENIRRIs project, along with future upcoming multidisciplinary educational
projects and patient–professional collaborations, will contribute to better clarify the clinical impact of such
diseases with the aim being to optimise the management of critically ill patients with nosocomial
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respiratory infections. Finally, we hope that the results of the ENIRRIs project will help to answer some of
the research questions recently posed in the ERS, European Society of Intensive Care Medicine, European
Society of Clinical Microbiology and Infectious Diseases and Asociación Latinoamericana del Tórax
guidelines for HAP/VAP management [17].
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